Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer

Preclinical Efficacy and Safety Results Indicate AlloCAR T™ Development Candidate Controls Tumor Growth without Off-Tumor/Normal Tissue Toxicity SOUTH SAN FRANCISCO, Calif. , Jan. 25, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics , Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company